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ABSTRACT
Ethionamide is an antituberculous drug for the
treatment of multidrug-resistant Mycobacterium
tuberculosis. This antibiotic requires activation
by the monooxygenase EthA to exert its activity.
Production of EthA is controlled by the tran-
scriptional repressor EthR, a member of the TetR
family. The sensitivity of M. tuberculosis to
ethionamide can be artificially enhanced using syn-
thetic ligands of EthR that allosterically inactivate
its DNA-binding activity. Comparison of several
structures of EthR co-crystallized with various
ligands suggested that the structural reorganization
of EthR resulting in its inactivation is controlled by
a limited portion of the ligand-binding-pocket.
In silico simulation predicted that mutation G106W
may mimic ligands. X-ray crystallography of variant
G106W indeed revealed a protein structurally similar
to ligand-bound EthR. Surface plasmon resonance
experiments established that this variant is
unable to bind DNA, while thermal shift studies
demonstrated that mutation G106W stabilizes EthR
as strongly as ligands. Proton NMR of the methyl
regions showed a lesser contribution of exchange
broadening upon ligand binding, and the same
quenched dynamics was observed in apo-variant
G106W. Altogether, we here show that the area sur-
rounding Gly106 constitutes the molecular switch
involved in the conformational reorganization of
EthR. These results also shed light on the mechan-
istic of ligand-induced allosterism controlling the
DNA binding properties of TetR family repressors.
INTRODUCTION
Tuberculosis (TB) is the leading cause of death due to
a bacterial infection and accounts for 2.5% of all pre-
ventable deaths globally. The major obstacle to the
global control of tuberculosis is the difﬁculties to
detect and cure enough cases to interrupt transmission
(1). Moreover, development and transmission of
Mycobacterium tuberculosis strains resistant to multiple
antibiotics (MDR) are emerging problems of major
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higher than the one associated to drug-sensitive TB.
MDR-TB patients require specialized antibiotics often
associated to serious side effects, which weaken the obser-
vance and lead to treatment failure. In addition, patients
infected with MDR-TB remain infectious for longer
than patients infected with drug-sensitive strains. Multi-
parametric strategies are needed in order to break this
vicious circle. Identiﬁcation of new molecules active
against yet unexploited targets is obviously essential and
recent efforts have led to the discovery of such promising
compounds. It is, however, likely that these new antibiot-
ics will need to be used in combination with drugs of the
current regimens (2). Thus, improvement of the existing
treatments should be considered with the aim of reducing
their toxicity, thus favoring observance and eventually
boosting treatment success (3).
In previous studies, we and others showed that sensitiv-
ity of M. tuberculosis to pro-antibiotics such as isoniazid
(4), pyrazinamide (5), ethionamide (ETH) (6,7) and
thiacetazone (8) is limited by the suboptimal activity of
mycobacterial enzymes responsible for their bioactivation.
In particular, ETH needs to be bioactivated by the myco-
bacterial monooxygenase EthA to acquire its antibacterial
properties. The production of EthA is controlled by
EthR, a mycobacterial transcriptional repressor of the
TetR family. Deregulation of the production of EthA
obtained experimentally by genetic inactivation of
the EthR coding gene demonstrated that this repressor is
responsible for a signiﬁcant level of natural resistance of
M. tuberculosis to ETH (6). Studies of the mechanisms of
repression of ethA by EthR revealed that this repressor
of the TetR family binds DNA as four dimers overlapping
as much as 55bp located upstream the ethA open reading
frame (9), thus congesting the transcription initiation
site of this gene.
Equilibrium between repression and derepression of
genes regulated by TetR-type of repressors has been
mainly shown to be controlled by ligands (10), with
notable exceptions such as AmtR, which is controlled by
protein complex formation (11). At critical concentra-
tions, these ligands induce conformational modiﬁcations
of the repressors, eventually transmitted to characteristic
mirrored DNA binding motifs, leading to the release of
the protein from DNA. Two independent crystal struc-
tures of EthR conﬁrmed typical structurally conserved
helix-turn-helix (HTH) DNA binding motifs within an
N-terminal three-helix bundle and a larger C-terminal
helical domain of dimerization. More importantly, both
structures revealed fortuitous and highly different ligands
in the repressor. The ﬁrst structure was characterized by
the presence of hexadecyl octanoate in the core domain of
each monomer of EthR (PDB: 1U9N), thus revealing the
long linear ligand binding pocket of the repressor (3). The
other structure revealed the presence of two 6-membered
cyclic molecules, possibly dioxane, in the ligand binding
pocket of each monomer (PDB: 1T56) (12). By compari-
son with other members of the TetR family, the presence
of either hexadecyl-octanoate or dioxane is translated in
structural modiﬁcations of the DNA binding heads which
keep them in a conﬁguration incompatible with DNA
binding (13).
With the objective of increasing the sensitivity of
M. tuberculosis to ETH, we recently designed synthetic
ligands to speciﬁcally bind the ligand binding site of
EthR and we demonstrated their capacity to inhibit
EthR–DNA interactions (14). Bacteria treated with such
EthR-inhibitors showed a substantial increase of ethA
mRNA production which was then correlated to a
20-time increase of sensitivity to ETH. Finally, one
ligand was able to triple the efﬁciency of ETH on a
TB-infected mice model. Fortuitous and synthetic
ligands of EthR identiﬁed so far interact with various
sections of the ligand binding pocket of the regulator.
Interestingly, crystal structures revealed that while the
pocket of EthR is able to accept very long ligands (3),
smaller molecules with occupancy limited to the upper
part of the pocket are sufﬁcient to induce conformational
changes impairing the repressor function of the protein
(12,14–16).
In the present study, we have compared all these
structures to delineate the common structural region of
EthR involved in the interaction with different ligands.
This allowed us to propose a minimal region of interaction
between EthR and ligand necessary for inducing the struc-
tural movements of the DNA binding motifs. In silico
simulations of amino acid replacement followed by experi-
mental validation conﬁrmed the predominant role of the
G106 region for ligand recognition process and for the
initiation of the structural reorganization of the regulator.
These results will help drive the development of improved
synthetic EthR inhibitors towards reduced ETH dosage
treatment. Importantly, these data contribute to the
basic understanding of the intramolecular communication
between the ligand binding domain and the DNA binding
domain in TetR type repressors.
MATERIALS AND METHODS
Construction of pET15b-ethR-G106W
A ﬁrst PCR product was obtained by ampliﬁcation using
M. tuberculosis H37Rv chromosomic DNA as template
and oligonucleotides O-275 (50AGGACCGTCCGCTGG
CCGATA-30) and O-276 (50AACACGTTGATCCAGGT
GCGCCACA-30) as primers, thus introducing a point
mutation at codon 106 of ethR (underlined in oligonucleo-
tide O-276), resulting in the replacement of Glycin 106
by a tryptophane. This 216-bp fragment was used as
a5 0 primer in association with oligonucleotide O-278
(50GCTTCCTTTCGGGCTTTGTTAGCAG-30)t o
amplify a 594-bp fragment, which was subsequently
inserted in PCRII-Topo (Invitrogen) to generate
pCRIIethRG106W. The 275-bp SalI–SalI fragment of
pET15b-ethR (9) was then exchanged for the equivalent
fragment of pCRIIethRG106W to produce pET15b-
ethR-G106W. The orientation of the fragment was
checked by restriction and the DNA sequence was
conﬁrmed by sequencing of the entire ORF.
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EthRG106W
N-terminally hexa-histidine-tagged EthR WT or
EthRG106W were produced in Escherichia coli C41 using
the protein expression plasmids pET15b-ethR and
pET15b-ethR-G106W, respectively, as previously
described (9). Bacteria were grown at 37 C in 100ml LB
broth to an OD600nm of 0.6–0.7. Isopropylthiogalactoside
(IPTG) was then added to a ﬁnal concentration of 1mM
and the culture was grown for 3h at 37 C. The cells were
harvested by centrifugation at 12000g at 4 C, resuspended
in 10ml of lysis buffer (50mM Tris/HCl, 300mM NaCl,
pH 7.5, 10mM imidazole) and lysed by two passages at
6.2MPa through a French Press cell. After centrifugation
(20000g, 25min, 4 C), the supernatant was recovered and
EthR or EthR-G106W was separated from the whole-cell
lysate by Ni-NTA agarose chromatography (Qiagen).
After three washing steps with lysis buffer, His6-tagged
proteins were eluted from the resin with 250mM imid-
azole in lysis buffer, dialyzed overnight against EthR
Buffer (10mM Tris/HCl, 300mM NaCl, pH 7.5, 1mM
DTT, 0.1mM EDTA). Protein purity was controlled by
Coomassie blue staining after SDS–PAGE on a 12% poly-
acrylamide gel. Protein concentration was evaluated using
the Bio-Rad protein assay kit. Puriﬁed proteins EthR and
EthR-G106W were stored in EthR Buffer at 4 C.
Synthesis of EthR ligands
BDM14801, BDM31343 and BDM31381 were syn-
thesized according to published procedures (14,16,17).
BDM33066 [(S)-2-Amino-3-methyl-1-[4-(3-thiophen-2-yl-
1,2,4-oxadiazol-5-yl)-piperidin-1-yl]-butan-1-one hydro-
chloride] was synthesized as follow: N-Boc-L-Valine
(1.2eq.), EDCI (1.2eq.), HOBt (0.5eq.) and triethylamine
(4eq.) were mixed in DCM (2ml) for 5min. Then
4-(3-Thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-piperidine
hydrochloride (150mg, 0.5mmol, 1eq.) in 3ml of DCM
was added. The reaction mixture was stirred overnight
at room temperature then evaporated under reduced
pressure. The residue was puriﬁed by thick layer chroma-
tography (DCM/MeOH 98/2) (Yield=61%). Boc inter-
mediate was deprotected using hydrogen chloride 4 N
solution in dioxane (5eq.). The residue was puriﬁed by
thick layer chromatography (DCM/MeOH 9/1) to give
BDM33066. Yield 66%;
1H NMR (MeOD) d 7.78
(dd, J=3.6Hz J=1.2Hz, 1H), 7.68 (dd, J=5.1Hz
J=1.2Hz, 1H), 7.20 (dd, J=5.1Hz J=3.6Hz, 1H),
4.40–4.59 (m, 1H), 4.23–4.30 (m, 1H), 3.99–4.09 (m,
1H), 3.41–3.46 (m, 2H), 3.00–3.18 (m, 1H), 2.13–2.29
(m, 3H), 1.81–2.01 (m, 2H), 1.10 (d, J=7.2Hz, 3H),
1.02 (d, J=6.9Hz, 3H). tRLCMS 3.9min. Purity 99%
MS [M+H]
+ m/z 335. NMR spectra were recorded on a
Bruker DRX-300 spectrometer. Chemical shifts are in
parts per million (ppm). Mass spectra were recorded
with a LC-MSMS triple-quadrupole system (Varian 1200
ws). LCMS analysis was performed on a C18 TSK-GEL
Super ODS 2mm particle size column, 50 4.6mm using a
gradient starting from 100% H2O/0.1% formic acid and
reaching 20% H2O/80% CH3CN/0.08% formic acid
within 10min at a ﬂow rate of 1ml/min.
Crystal structure of EthRG106W and ligand complexes
Prior to crystallization, the protein was buffer exchanged
against 10mM Tris–HCl (pH 7.5), 200mM NaCl
and concentrated to 9mg/ml. We obtained crystals of
EthRG106W, and cocrystals of EthR with ligands
BDM33066 and BDM31343 by the vapor diffusion
method. EthRG106W and EthR-BDM33066 were cryst-
allized using 0.17M ammonium sulfate, 0.085M sodium
cacodylate (pH 6.5), 15% glycerol and 25–35% polyethyl-
ene glycol 8000 as the crystallization solution. Co-crystals
of EthR-BDM31343 were produced using 1.4–1.65M
ammonium sulfate (using 0.05M increment), 15%
glycerol and 0.1M MES pH 6.7. The EthR ligand
complexes were prepared by mixing 1ml of ligand
(33mM in 100% DMSO) and 9ml of the puriﬁed pro-
tein (9mg/ml). Crystal structures of EthR in complex
with BDM14801 (PDB#3O8G) and BDM31381
(PDB#3G1M) were reported previously (14,16).
All crystal obtained belong to space group P41212, and
thus displays a packing similar to the WT and other pre-
viously solved EthR structures. Data collection statistics
for all structures are reported in Table 1. Diffraction data
were processed with X-ray Detector Software (http://xds
.mpimf-heidelberg.mpg.de/) (18). Phasing for the G106W
mutant was accomplished by positioning the WT EthR
structure using a rigid body minimization procedure,
whereas phasing of liganded EthR structures were
achieved by molecular replacement method using
MolRep program (19). Structure reﬁnements were done
with program REFMAC5 (20) from the CCP4 suite
(21). The G106W mutation was clearly visible in the
electron density map. The Trp residue at position 106
was introduced and ﬁtted into the electron density map
using Coot (22) as well as the corrections of the conform-
ation of adjacent residues. The ﬁnal Rfactor at 1.86A ˚
resolution is 17.7% (Rfree of 22.9%) with a good
geometry for the structure. The coordinates of the
EthRG106W mutant and co-crystals of EthR with
BDM33066 and BDM31343 have been deposited with
the PDB data bank under the accession codes 3TP3,
3Q0W and 3TP0, respectively. Data collection and
reﬁnement statistics for all structures are reported in
Table 1. Figures were prepared with PyMOL (http://
www.pymol.org/).
Structural alignment of the different EthR structures
was performed with Pymol and pairwise structure com-
parisons with DaliLite program (23). Supplementary
Table S1 shows the RMS values obtained by pairwise
structure superposition of the dimerization domain
(from Lys68 to the C-terminus) of the six-liganded
EthR structures.
Surface plasmon resonance binding assay
Real-time analysis of molecular interactions between
EthR and the ethA promoter region was conducted on
a Biacore
TM 2000 apparatus (GE Healthcare). The
ethA–ethR intergenic region was obtained by PCR using
H37Rv chromosomal DNA as template and the following
oligonucleotides: O-270: 50-CGGTCATGGATCCACGC
TATCAAC-30 and O-271: 50-biotin-CTGACTGGCCGC
3020 Nucleic Acids Research, 2012,Vol.40, No. 7GGAGGTGGT-30. The ampliﬁed biotinylated DNA was
puriﬁed on a Qiaquick column (Qiagen) and sequenced for
veriﬁcation. Immobilization of the DNA was performed
on a streptavidin-coupled CM5 Sensor Chip using the
standard protocol provided with the Amine Coupling
Kit (Biacore
TM). Brieﬂy, streptavidin was injected at
500ng/ml in 10mM sodium acetate (pH 3.5) for 12min
at a ﬂow rate of 10m/min. The biotinylated DNA
( 69kDa) was injected through each ﬂow cell at 200ng/
ml to reach a 205 resonance unit (RU) stable ﬁxation to
streptavidin. We controlled the integrity and quantity of
ﬁxed DNA with a 120-s injection of 1.6mM calf histone
H1 (Sigma) at 10m/min. Binding experiments of EthR and
EthR-G106W to DNA were conducted in EthR-Buffer at
a ﬂow rate of 20m/min at 25 C. The protein was injected
at 0.3mM (concentration of the monomer) in the running
buffer until equilibrium was reached. The Sensor Chip was
regenerated by a 60-s injection of 0.03% SDS. Final
curves presented in this document are representative of
experiments repeated a minimum of four times and were
obtained by substraction of the signal corresponding to a
control ﬂow cell functionalized with a double stranded
irrelevant DNA fragment (internal fragment of the
E. coli bla gene).
Thermal shift assay
The ﬂuorescent dye SYPRO Orange (Invitrogen) was used
to monitor protein unfolding. This dye is environmentally
sensitive and leads to an increase in ﬂuorescence following
exposure of hydrophobic regions during protein
unfolding. The thermal shift assay was conducted in a
Lightcycler 480 (Roche). The system contained a
heating/cooling device for temperature control and
a charge-coupled device (CCD) detector for real-time
imaging of the ﬂuorescence changes in the wells of the
microplate. The ﬁnal sample concentrations were 10mM
EthR, 2.5  SYPRO Orange, 1% DMSO and 20mM
ligand in EthR buffer (10mM Tris/HCl, 300mM NaCl,
pH 7.5, 1mM DTT, 0.1mM EDTA). Samples were heated
from 37 Ct o8 5  C with a heating rate of 0.04 C/s. Protein
unfolding was monitored by recording changes in the
ﬂuorescence of SYPRO Orange. Fluorescence intensity
was measured at Ex/Em: 465/510nm. The inﬂection
point of the curves was determined by plotting the ﬁrst
derivative dFI/dT, and the melting temperatures (Tm)
were assessed from the maxima.
NMR spectroscopy
Proton spectra were recorded on a 27-mg/ml EthR sample
in 300mM NaCl, 10mM Tris-d7 pH 7 aqueous buffer, at
30 C. Spectra were recorded with 128 scans on a 600-MHz
AvanceI Bruker spectrometer (Karlsruhe, Germany)
equipped with a cryogenic triple resonance probe head,
and used excitation sculping for water suppression (24).
Ligand BDM31381 was dissolved in DMSO-d6 and added
to the EthR sample at a 1:1 ratio and at a ﬁnal concen-
tration of 1% DMSO-d6. An equivalent experiment using
1% DMSO-d6 without ligand was done to verify that
DMSO at this concentration does not alter the spectrum
of the apo-protein. The concentration of EthRG106W was
15mg/ml, and spectra were recorded with 512 scans.
Isothermal titration calorimetry
ITC experiments were conducted in a VP-ITC Unit
(MicroCal, Northampton, MA, USA), with 12.5mM
EthR (wild-type or G106W variant) in the cell
Table 1. Data collection and reﬁnement statistics
EthRG106W EthR-BDM33066 EthR-BDM31343
Data collection
X-ray source rotating anode ESRF ID23 SLS PXIII
Space group P41212P 4 1212P 4 1212
Cell dimensions
A, b, c (A ˚ ) 119.7, 119.7, 33.7 119.8, 119.8, 33.6 119.1, 119.1, 33.6
 ,  ,   ( ) 9 09 09 0
Resolution (A ˚ ) 1.86 (1.86–1.91)
a 1.6 (1.6–1.7) 1.89 (1.89–1.94)
I/sI 22.1 (4.9) 17.7 (4.1) 17.8 (4.3)
Completeness (%) 97.75 (91.8) 99.8 (100) 100 (100)
Reﬁnement
Resolution (A ˚ ) 1.86 1.6 1.9
No. reﬂections 19529 31208 18656
Rwork/Rfree 17.7/22.9 19.2/23.3 19.2/25.6
No. atoms
Protein 1531 1502 1470
Ligand/ion – 23 21
Water 216 160 81
B-factors
Protein 18.6 22.1 29.7
Ligand/ion – 25 27.9
Water 32 33.7 41.1
RMSDs
Bond lengths (A ˚ ) 0.013 0.028 0.022
Bond angles ( ) 1.29 2.5 1.9
aNumber in parentheses is the statistic for the highest resolution shell.
Nucleic Acids Research,2012, Vol.40, No. 7 3021compartment and 0.3mM of BDM14801 in the titrating
syringe. ITC curves presented in this document are repre-
sentative of experiments repeated four times with EthR
WT and two times with the G106W variant. Both
protein and ligand were prepared in EthR buffer contain-
ing 1% DMSO and without DTT. The protein was
titrated at 25 C with 40 5ml injections of the ligand.
The duration of each injection was 10s with 240s
spacing. The stirring speed during the titration was
300rpm. Data were analyzed using Microcal Origin
software by ﬁtting the curves to a single-site binding
model.
RESULTS
Determination of the minimal ligand binding site of EthR
Crystal structures of six holo-forms of EthR were chosen
for tridimensional superimposition (Figure 1). The two
ﬁrst structures are holo-forms of EthR involving ligands
fortuitously co-crystallized with the repressor. The ﬁrst
structure shows the 24-carbon long ligand (hexadecyl
Octanoate, PDB access#1U9N) invading each of the
hydrophobic pockets existing in the two monomers
forming EthR (Figure 1a) (3). The 3D structure of the
second crystal (PDB access#1T56) is nearly identical to
the structure 1U9N (0.67A ˚ RMSD) but instead of one
long linear hydrophobic ligand, this crystal exhibits
two dioxanes embedded in each monomer of EthR
(Figure 1b) (12). Co-crystals of EthR with four synthetic
compounds are also depicted in Figure 1c–f. BDM14801
(PDB#3O8G), BDM31381 (PDB#3G1M), BDM31343
(PDB#3TP0) and BDM33066 (PDB#3Q0W) are com-
pounds that bear two hydrophobic ends connected by
a 4–6-A ˚ linker (14). These compounds where initially
designed to ‘mimic’ the mode of binding of the two
cyclic compounds present in the ligand binding pocket
of 1T56 and to offer hydrogen bonding capabilities set
to interact with Asn176 and Asn179 of EthR. In all four
cases, the co-crystals revealed that occupation of the
binding pocket by these compounds induces structural
reorganization of the HTH regions equivalent to the one
observed in crystal structures 1T56 and 1U9N. More
precisely, in the six cases analyzed here, distance
between the P59 (Ca) of each HTH motifs [corresponding
to P39 in TetR (25) and to G37 in QacR (26)] are
comprised between 42 and 47A ˚ . These HTH spacings
are much larger than the 34- to 37-A ˚ distance observed
in co-crystallized repressor-operator complexes (26–30).
In contrast to this consistent structural effect, the local-
izations of these various ligands in the hydrophobic
pocket of EthR as well as their interactions with various
amino acids of the protein are rather heterogeneous.
The hexadecyl-octanoate embedded in structure 1U9N is
 27A ˚ long and thus potentially contacts >30 amino acids
delimiting the ligand pocket of EthR, including some
deeply located in the pocket close to the HTH domain.
On the other hand, the two small cyclic molecules
described in 1T56 are located respectively in the upper
and mid part of the pocket and thus, contact a much
more limited number of amino acids. As depicted in two
previous reports, BDM31381 and BDM14801 occupied
the same region than the one in contact with the
two dioxane of 1T56 (14,16). The co-crystal EthR-
BDM31343 presented here led to the same observation,
conﬁrming the implication of this portion of the pocket
in the structural induction of the repressor. Moreover,
these three ligands are hydrogen-bonded to the side
chain of N179 through their common amide function.
Recently, we performed an extensive structure-activity
relationship study of BDM31343, which included the
replacement of its cyanoacetyl group (15). Some of the
ligands identiﬁed during this process were cocrystallized
with EthR. Surprisingly, BDM33066 revealed to be
located higher in the binding pocket of EthR and in
the opposite orientation compared to its progenitor
BDM31343 (Figure 1e). As such, the thiophene moiety
of BDM33066 occupied the region corresponding to
the uppermost dioxane described in structure 1T56.
Nevertheless, these limited ligand–protein contacts were
sufﬁcient to promote a structural reorganization of the
HTH motifs globally equivalent to the one observed
with the other compounds.
Superimposition of these six structures of EthR
co-crystallized with fortuitous or synthetic ligands
revealed very weak tridimensional variations (pairwise
RMSD in the range of 0.3–0.7A ˚ ; see Supplementary
Table S1), and thus allowed to delimit a narrow
tridimensional space shared by all compounds. As
illustrated in Figure 1g, this space corresponds to the
C18–C20 portion of hexadecyl-octanoate, to the upper
dioxane present in structure 1T56, to the piperidine
group of either BDM31381, BDM14801 or BDM31343,
and to the thiophene portion of BDM33066. These obser-
vations invited us to hypothesize that contacts between
ligands and EthR within this very limited region of the
pocket could be sufﬁcient to initiate a spatial reorganiza-
tion of the two HTH motifs of the repressor leading
to a conformation incompatible with DNA binding.
The superimposition of the ligands not only allowed to
point amino acids of the pocket potentially involved in the
structural switch of EthR but also revealed some strong
spatial constrains imposed to all ligands in this region.
As illustrated in Figure 2a, the spatial portion common
to all ligands share the same geometry plane.
We then hypothesized that both steric and spatial
hindrance imposed by the ligands to this portion of the
binding pocket could be mimicked by the side chain of an
amino acid artiﬁcially introduced in this region of the
protein, advantageously by an amino acid residue
bearing a planar hydrophobic side chain such as phenyl-
alanine, tyrosine or tryptophane.
Systematic substitution of amino acids located in this
region of the ligand binding pocket by hydrophobic
residues was simulated using the mutagenesis tool of
Pymol (Mutagenesis Wizard, Schrodinger, LLC).
Replacement of amino acids A83, L87, L90, M102,
G106, T149, V152 and L175 by Phe, Tyr or Trp were
evaluated (data not shown). Replacement of G106 by
Trp (Figure 2b) was the most promising change that
could advantageously mimic the encumbrance of the
common portion of all ligands (the piperidine group of
3022 Nucleic Acids Research, 2012,Vol.40, No. 7either BDM31381, BDM14801 and BDM31343, the
thiophenyl group of BDM33066 or the upper dioxane
present in 1T56).
EthR mutagenesis and crystal structure
Mutation G106W was introduced in His-tagged EthR by
side direct mutagenesis, the protein was produced in
E. coli and puriﬁed on Nickel-afﬁnity column. The
crystal structure of EthRG106W was determined at a reso-
lution of 1.86A ˚ starting from the coordinates of the
wild-type protein, allowing to evaluate the structural
impact of the G106W mutation. The obtained crystals
belong to space group P41212 with unit cell parameters
a=b=119.7A ˚ and c=33.7A ˚ which corresponds to
the space group obtained in our previous studies of
liganded EthR (3), demonstrating that mutation G106W
does not destabilize or deeply modify the overall structure
of the repressor.
Detailed analysis of this structure revealed that the
values of backbone dihedral angles phi/psi do not
change upon mutation G106W, remaining around  70 /
 50 . Thus, the indole group of W106 (Figure 3a)
occupies the volume otherwise ﬁlled by the common
portion of ligands, for instance the thiophene moiety of
BDM33066 (Figure 3b).
Interestingly, the electron density map revealed that
EthRG106W is a ligand-free protein. Compared to the
pocket containing hexadecyl-octanoate observed in struc-
ture 1U9N, the absence of ligand in EthRG106W permits
the reorganization of some amino acids (Figure 3c).
The benzyl side chain of F141 is now tilted inside the
empty pocket, which forces the indole group of W145 to
rotate 180  upwards, thus ﬁlling the free space located
(a)
(b)
(c)
(g)
(d)
(e)
(f)
Figure 1. Determination of the ‘minimal ligand binding site’ of EthR. Crystal structure of the ligand binding site of six holoforms of EthR:
(a) EthR-hexadecyl-octanoate (PDB#1U9N), (b) EthR-Dioxane (PDB#1T56), (c) EthR-BDM31381 (PDB#3G1M), (d) EthR-BDM14801
(PDB#3O8G), (e) EthR-BDM31343 (3TP0) and (f) EthR-BDM33066 (PDB#3Q0W). Close-views of the occupancy of each ligand in the binding
pocket of EthR. The protein is displayed in ribbon and the side chain of Asn179 is represented by sticks colored according the following atom color
schemes: carbon in blue, oxygen in red and nitrogen in dark blue. When observed, hydrogen bonds with this latter side chain are depicted by dashed
lines with the interacting distance indicated. (g) Superimposition of the six crystal structures. The cyclic moieties of BDM14801 (orange), BDM31381
(red), BDM33066 (dark blue), BDM31343 (light blue), the C18–C20 portion of hexadecyl-octanoate (yellow) and the upper dioxane (pink) share
a narrow space delimited with the gray translucent disk.
Nucleic Acids Research,2012, Vol.40, No. 7 3023in-between L87 and K144, also resulting in a slide push of
Y148 (Figure 3c). Changes are also observed in the
bottom part of the pocket. The side chains of F184 and
Q125 now invade the empty ligand binding pocket and
R128 freely spreads out its side chain perpendicularly to
the tunnel (Figure 3c). The most important observation
refers to the conformation of the DNA binding motifs of
this variant of EthR. Even though this mutated protein
does not contain any ligand in its binding pocket, X-ray
data revealed that the distance separating the P59 (Ca)
of each HTH motifs is 42.3A ˚ (Figure 3d).
Binding of EthRG106W to DNA
With its DNA recognition helices a3 and a30 separated by
41.5A ˚ , the G106W variant of EthR was predicted to be
unable to bind its DNA operator, as this distance amply
exceeds the helical periodicity of the B-DNA double helix
(34A ˚ per turn of the helix). However, it could be possible
that the conformation revealed by the crystal structure
reﬂects a peculiar conformational state of EthRG106W
that is not necessarily representative of the conformation
and dynamics of the protein in solution (31). Thus, the
capacity of the variant repressor EthRG106W to interact
with its DNA operator in solution was investigated by
surface plasmon resonance (SPR) and compared to that
of EthR. As described previously (9), EthR bound specif-
ically and cooperatively to its 55bp operator located in
the intergenic region separating ethA and ethR. On the
contrary, injection of EthRG106W onto the same
sensorchip revealed a total absence of interaction with
the DNA operator (Figure 4). This data experimentally
conﬁrms that mutation G106W abolishes the capacity
of binding of EthRG106W to its DNA operator in
solution, in agreement with the HTH architecture of the
variant repressor revealed by X-ray crystallography
(Figure 3d).
Comparative folding behavior properties of EthRG106W
and EthR
Crystallography studies revealed that variant protein
EthRG106W is in a conformation equivalent to the one
observed in ligand–EthR co-crystals and that both situ-
ations translate in incompatibility with DNA binding as
measured by SPR. Hence, we attempted to compare the
impact on folding stability of the G106W mutation with
the one resulting from the binding of speciﬁc ligands to
the repressor. Monitoring of the thermal unfolding was
performed using a ﬂuorescence-based thermal shift
(a)( b)
Figure 2. In silico mutagenesis model of G106W. (a) Front and 90  lateral views of the superimposition of the ligands in their respective position in
the ligand binding pocket of EthR. The gray rectangle highlights the zone common to all ligands. (b) Front and 90  lateral views of the in silico
substitution of glycine 106 for tryptophan.
3024 Nucleic Acids Research, 2012,Vol.40, No. 7assay (TSA) (32,33). The method takes advantage of the
differential behavior of hydrophobic ﬂuorophores upon
exposure to folded or to unfolded protein. The ﬂuores-
cence of probes such as SYPRO Orange is quenched in
aqueous solution but is restored when it contacts
hydrophobic regions of protein exposed upon unfolding.
Fluorescence emission can be studied as a function of tem-
perature, which provides a melting curve revealing the
thermal stability of a protein or complexes. The thermal
unfolding curves of EthR and EthRG106W were
(a)
(b)
(c)( d)
Figure 3. Crystallographic structure of EthRG106W.( a) Close view of the indole group of tryptophan 106 as observed in the crystal structure of the
variant EthRG106W (PDB#3TP3). (b) Close view of the same region superimposed with the crystal structure of EthR-BDM 33066 (ligand BDM 33066
is shown in purple). (c) Superimposition of EthRG106W (Gold) and EthR-hexadecyl-octanoate (Pink). Only selected amino acid side chains are shown.
Reorganization of amino acid side chains in the north part (upper panel) and in the south part (lower panel) of the ligand binding pocket.
(d) Measurements of the distance separating the two helix-turn-helix DNA-binding motifs (a carbon of P59’s) in the variant EthRG106W.
Figure 4. Binding of EthR and EthRG106W to the DNA operator of ethA measured by surface plasmon resonance. Sensorgram showing two
successive injections of 0.3mM EthR (at 500 and 1000s) on a sensor chip functionalized with 250 arbitrary RU of the biotinylated intergenic
ethA-R DNA region (9), followed by the injection of 0.3mM EthRG106W (at 1600s). A third injection of 0.3mM EthR was done (at 2100s) to control
the binding capacity of the chip after the previous injection of EthRG106W. Arrows indicate time of protein injection.
Nucleic Acids Research,2012, Vol.40, No. 7 3025determined using a Q-RT-PCR thermo cycler (Light
Cycler Roche 480). As shown in Figure 5a, the unfolding
of EthR and EthRG106W followed a two-state transition as
the ﬂuorescence intensity (FI) increased during the pro-
gressive unfolding of the protein, reached the plateau
and then decreased due to aggregation of denatured
Figure 5. Binding of ligands to EthR and EthRG106W.( a) Thermal stability of EthR (dashed curve) and EthRG106W (plain curve). Curves correspond
to the ﬁrst derivative of the ﬂuorescence of Sypro Orange recorded during samples denaturation (30 values per  C). Melting temperature (Tm) for
each sample corresponds to the maxima of the curve. (b) Tm of EthR and EthRG106W in the presence of indicated ligands. (c) Isothermal Titration
Calorimetry study of the binding of BDM14801 to EthR (left) and EthRG106W (right). The graph shows raw data of a typical experiment, expressed
inmcal/s versus time units.
3026 Nucleic Acids Research, 2012,Vol.40, No. 7protein–dye complex (32). Respective melting tempera-
tures (Tm) were deduced by extracting the maximum of
the ﬁrst order derivative of the melting curves ﬂuorescence
data (dFI/dT). Under equivalent experimental conditions,
the average Tm of EthR and of EthRG106W were respect-
ively 62.2 C±0.3 and 70.7 C±0.1, revealing a much
higher thermal stability of the variant protein compared
to the wild-type (Figure 5a).
We then compared the stabilization effect brought
by the G106W mutation with the one obtained when
EthR was mixed with various known synthetic ligands.
Three synthetic ligands (BDM14801, BDM31343 and
BDM31381) of EthR were selected based on their
capacities to inhibit EthR–DNA interactions in vitro
(14,16). The thermal stability curves corresponding to
the three complexes EthR-BDM14801, EthR-BDM31343
and EthR-BDM31381 were recorded and compared to the
ones obtained for EthR and EthRG106W. Figure 5b shows
that BDM31381 is the compound that induced the highest
Tm when it binds to EthR (72.1 C±0.4), followed by
BDM14801 with 67.7 C±0.5 and by BDM31343 with
a Tm of 65.9 C±0.1. Interestingly, thermostability gain
associated to mutation G106W appears more important
than the one observed when EthR was mixed with ligands
BDM31343 and BDM14801, and slightly less important
than the one observed for the complex EthR-BDM31381.
Altogether, these data correlated well with our previous
SPR results showing that BDM31381 was more efﬁcient
than BDM14801, itself more active than BDM31343
in impairing the capacity of EthR to bind its DNA
operator (14). In conclusion, the thermal stabilization of
EthR brought by mutation G106W is equivalent to the
one brought by highly efﬁcient ligands of the repressor.
To test whether high afﬁnity EthR ligands could force a
relocalization of the indole side chain of W106 to invade
the pocket, we measured the capacity of the three ligands
to improve the thermal stability of EthRG106W. None of
them was able to modify the midpoint transition tempera-
tures of the mutated protein (Figure 5b). Interestingly,
even BDM31381, with its ability to stabilize the WT
protein at a temperature superior than the melting tem-
perature of EthRG106W, was unable to modify the melting
temperature of the variant protein.
As it cannot be excluded that interaction of ligands with
EthRG106W is undetectable by TSA due to the high
thermostability of this variant protein, we used isothermal
titration calorimetry. We ﬁrst measured whether the for-
mation of the EthR-BDM14801 complex is exothermic
or endothermic. Figure 5c (left panel) shows a typical
titration at 25 C of EthR (12.5mM) by serial injections
of BDM14801 (0.3mM). This experiment revealed that
heat was released when EthR associated with this ligand.
A similar experiment was repeated to determine whether
BDM14801 interact with the variant protein EthRG106W.
As shown in Figure 5c (right panel), no heat change could
be detected when 0.3mM BDM14801 was injected into the
adiabatic cell containing 12.5mM EthRG106W. This result
conﬁrms that the variant protein EthRG106W has com-
pletely lost its capacity to interact with ligands that bind
the wild-type protein with a high afﬁnity.
Probing the protein dynamics with NMR spectroscopy
Altogether the parallelism between the mechanism of
inhibition by ligands and by the G106W mutation
suggests that the increased rigidity of the structure in an
‘open HTH form’, which translates in the observed
improved thermostability, may be the underlying mechan-
ism leading to the loss of the DNA-binding function of
EthR (34). To collect direct evidence for a possible
mechanism of ligand-induced rigidiﬁcation that would
be paralleled by the G106W mutation, we performed
NMR spectroscopy of the proteins in the absence and
presence of ligands. Whereas heteronuclear NMR of the
50-kDa dimer is beyond reach at this moment, we focused
on the well-resolved upﬁeld shifted methyl resonances.
Chemical shift prediction by ShiftX2 (35) based on the
crystal structures identiﬁed a number of methyls with
upﬁeld shifted resonances, mainly belonging to residues
that surround the hydrophobic ligand binding pocket
(Supplementary Figure S1). Although the prediction
itself might not be reliable enough to assign them individu-
ally, the set of methyl resonances detected at resonance
frequencies <0.5ppm is expected to correspond to those
methyls. In the apo-EthR spectrum, they are hardly
detectable as broad humps, but they do signiﬁcantly
sharpen in the presence of ligand BDM31381 (Figure 6,
lower and middle traces). As the size of the dimeric
complex and subsequent slow tumbling do not vary
upon ligand binding, we can exclude these factors as
sole source of line broadening. Slow movements of the
apo-protein on the micro- to millisecond time scale
equally can contribute to peak broadening in a process
called ‘exchange broadening’ (36), whereas these latter
movements appear quenched upon ligand binding. Most
importantly, however, we observe similar sharp lines
directly with the G106W variant, before adding any
ligand (Figure 6, upper trace). This unambiguously indi-
cates that the inﬂuence of the ligand on the motional
regime at equilibrium (in the thermodynamic sense) is
mimicked in a good manner by the sole G106W
mutation. The average position of the side chains pre-
dicted with upﬁeld shifted methyls does not vary
between the ligand bound WT and G106W mutant
proteins, as evidenced by our crystal structures, explaining
why these resonances do not shift their position.
DISCUSSION
EthR is a transcriptional regulator of the TetR family.
EthR regulates the production of EthA, a monooxygenase
implicated in the bioactivation of the antimycobacterial
prodrug ETH. Our previous works showed that synthetic
compounds mimicking fortuitous ligands of EthR inhibit
EthR, and consequently, increase ETH bioactivation
through the overproduction of EthA. Inhibition of the
DNA binding function of EthR by these ligands follows
a mode of action typical in the TetR family of repressors.
In these dimeric regulators, invasion of the binding
pockets by speciﬁc ligands results in the structural modi-
ﬁcations of the helix-turn-helix motifs of each monomer,
which translates in the loss of DNA recognition and
Nucleic Acids Research,2012, Vol.40, No. 7 3027binding to the repressor. The allosteric effect of the ligand,
meaning the structural mechanism by which binding of
molecules in the ligand pocket lead to the structural or-
ganization of distant motifs, is still not fully understood.
In the case of EthR, highly diverse ligands provoke
the structural modiﬁcations leading to a conformation
incompatible with DNA binding. This was shown with
molecules as different as the 24-carbon long hexadecyl
octanoate, small cyclic molecules such as dioxane, or
various structure-based designed synthetic inhibitors.
Here, we aligned liganded-EthR structures in order to
identify structural similarities that may explain how chem-
ically diverse ligands exert a common inhibitory effect on
EthR. Interestingly, the common portion of the binding
pocket of EthR that is in contact with every ligand is very
limited. In addition, intensive structure activity relation-
ship studies done to improve our synthetic ligands
demonstrated that important structural constrains are
required to allow ligand compatibility in this region
(14–16, M. Flipo et al., submitted for publication). The
goal of the actual study was to test whether this limited
zone of the pocket could be the hot-spot leading to the
allosteric response observed upon ligand binding, which
impact the spatial architecture of the helix-turn-helix
motifs of the repressor. Mutagenesis of glycine 106 to
tryptophan was introduced in order to mimic the effect
of ligands in this region of the pocket. This mutation
entailed structural modiﬁcations and thermostabilization
of the repressor equivalent to what was observed in the
presence of ligands.
First, X-ray structural analysis revealed that the HTH
DNA binding motifs of the mutated repressor are in
a conformation incompatible with DNA binding.
Indeed, EthRG106W shows a structural spacing of its
HTH domains (42.3A ˚ ) in the range observed in ligand–
protein complexes (42A ˚ with BDM31343 to 47A ˚ with
BDM14801) reinforcing the idea of mechanistic mimicry
between mutation G106W and ligands. Consistently, the
mutated repressor showed a complete incapacity to bind
to its DNA operator. Nevertheless, in their apo-form that
is by nature competent for DNA binding, the majority of
the regulators of the TetR family crystallizes in a conform-
ation clearly not compatible with DNA binding (37).
These observations led some authors to postulate that
crystal structures of apo-repressors of the TetR family
reﬂect only a snap shot of the conformational repertoire
of the proteins in solution and that the role of ligands
could be to stabilize one conformation of the repertoire
in which the recognition helices are too far apart to
simultaneously bind to adjacent major groove of DNA
(31,34,38).
If true, this stabilization should naturally translate in
some rigidiﬁcation of the protein upon binding of
ligand. Interestingly, the EthRG106W crystal reveals the
ﬁrst apo form of EthR. Our inability to succeed in
the crystallization of apo-form of the wild-type EthR
suggest that the major effect of the mutation, mimicking
ligands, was to improve the global stability of the protein.
Preliminary NMR experiments are in support of this
hypothesis, showing that a number of methyls of the
protein have indeed their NMR signal affected by
exchange broadening, reﬂecting typical dynamic processes
on the micro- to millisecond time scale, but both the
presence of ligand and the G106W mutation quench this
dynamics (Figure 6; Supplementary Figures S1 and S2).
From a thermodynamic point of view, fast internal
dynamics of the ligand binding pocket of EthR have the
potential to report on the number of states that the protein
explores, hence, acting as an indirect measure of the
residual entropy of the folded state. This observation
could somehow remind the transcription factor ETS,
for which ﬂexibility was shown to be directly correlated
to its capacity of binding to its DNA target (36).
Alternatively, the observed distance of >42A ˚ that
separate the HTH motifs in either EthRG106W or in
EthR–ligand complexes may by itself explain the inability
of the repressor to bound to its DNA operator, and the
drastic diminution of the internal ﬂexibility observed in
both cases could induce a locking mechanism to restrict
further conformational change, as proposed recently by
Le et al. (38) for SimR.
Intensive mutagenesis studies on TetR have led to the
identiﬁcation of many variants that are no longer able to
EthR G106W
EthR + BDM31381
Apo-EthREthR
Figure 6. Upﬁeld region of the 1D proton spectrum of apo-EthR
(bottom), EthR+ligand BDM31381 (middle) and apo-EthRG106W
(top). Signals in this region correspond to methyl protons whose
resonance is shifted out of the crowded methyl region (1.5–0.8ppm)
by the ring current effect of nearby aromatics (Full NMR spectra are
shown in Supplementary Figure S2). Prediction by ShiftX2 (35) shows
plausible candidates (Supplementary Figure S1). Whereas these reson-
ances are severely broadened in the apo-EthR spectrum, they sharpen
signiﬁcantly upon ligand addition or in the G106W mutant.
Resonances with conserved frequencies have been indicated by dotted
vertical lines. Differences between the most shifted resonances in the
EthR-ligand and EthRG106W mutant could come from a differential
magnetic inﬂuence of the ligand and the Trp side chain, and cannot
necessarily be interpreted in terms of structural differences.
3028 Nucleic Acids Research, 2012,Vol.40, No. 7bind to DNA, whereas there still show good afﬁnity for
tetracycline (39,40). Conversely, other variants that bind
DNA more strongly in the presence of tetracycline have
been described (41–44). Here, we have identiﬁed a variant
of EthR harboring the yet undescribed property to mimic
the allosteric effect of known ligands, resulting in the
complete inhibition of its DNA binding capacity. This
mutation not only mimics the activity of small molecule
ligands either at the functional level (inhibition of DNA
binding propensity), but also at the structural level
(equivalent structural conformations), or at the dynamic
level (rigidiﬁcation of the structure).
The design and improvement of high-afﬁnity inhibitors
in the context of drug discovery is a complex matter as the
increase of enthalpy through increased bond strength is
countervailed by the entropy reduction due to the global
increase of order of the system. In allosteric systems, it is
then essential to localize precisely the region of a protein
implicated in ligand-induced signal in order to facilitate
the design of structure-based inhibitors and maximize
their entropic and enthalpic contributions. The present
work used the large chemical and structural diversity of
known EthR’s ligands to identify one region of the protein
implicated in the allosteric response of its DNA binding
domain. Here, we have demonstrated that the inhibitory
effect of highly diverse speciﬁc ligands of EthR can be
mimicked by the mutation G106W. This now explains
how two small cyclic molecules such as dioxane (12)
induced the same conformational state as the one
induced with hexadecyl-octanoate (3,13). Conversely,
our results suggest that exploitation of deeper portions
of the ligand pocket to increase their afﬁnity/speciﬁcity
would be successful as long as these molecules interact
with the upper region of the pocket surrounding glycine
106.
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